JP5800454B2 - External preparation for skin, oral preparation, antioxidant, anti-aging agent, and immunostimulant - Google Patents

Description

  The present invention relates to a topical skin preparation, an oral preparation, an antioxidant, an anti-aging agent, and an immunostimulant containing a plant belonging to the genus Euglena.

  Causes of aging symptoms such as skin elasticity reduction and wrinkles with aging include decreased cell function, decreased or degenerated extracellular matrix components such as collagen, and oxidative damage of cells. In order to prevent and ameliorate such aging symptoms, various active ingredients have been searched for and studied for compounding. As an antioxidant, an extract of a plant belonging to the genus Salogaceae (see Patent Document 1), an extract of a plant belonging to the genus Helichrysum (see Patent Document 2), and an extract of gentian farelli (see Patent Document 3) are known. . Until now, it has not been known to use a plant belonging to the genus Euglena as a skin external preparation or the like.

JP-A-6-9391 JP 2007-16077 A Japanese Patent Laid-Open No. 2007-210962

  Naturally-derived components are known to have various pharmacological and cosmetic effects, and so far many plants and fungi have been widely applied to fields such as external preparations for skin and foods and drinks. However, there are many naturally-derived ingredients whose effects are not yet known, and the development of effective ingredients having excellent antioxidant action, anti-aging action, and immunostimulatory action has been expected. This invention is made | formed in order to find such an active ingredient, and makes it a subject to provide a skin external preparation, an oral preparation, an antioxidant, an anti-aging agent, and an immunostimulant.

  In order to solve the above-mentioned problems, the present inventors have studied various naturally-derived substances with respect to an antioxidant action, an anti-aging action, and an immunostimulatory action. As a result, they have found an excellent antioxidant action, anti-aging action, and immunostimulatory action in one or more plant extracts selected from the plant belonging to the genus Euthyrus, and have further studied and completed the present invention. .

  That is, the present invention relates to an external preparation for skin, an oral preparation, an antioxidant, an anti-aging agent, and an immunostimulant containing an extract of one or two or more kinds of plants selected from the plant belonging to the genus Euglena.

  ADVANTAGE OF THE INVENTION According to this invention, the skin external preparation, oral preparation, antioxidant, anti-aging agent, and immunostimulant which have the outstanding effect can be provided.

The plant used as the raw material of the present invention may be a plant of the genus Ranunculusaceae ( Anemon L.). The anemone plant, Ezoichige: Hiro Ha Himeichige (Anemone soyensis H.Boissieu), Himeichige: Himeichige So, Ichirinsou (Anemone debilis Fisch.): Ichigesou, Urabeniichige, Anemone pseudoaltaica Saw (Anemone nikoensis Maxim.): Chrysanthemum Zaki monophosphate Saw, Ruriichigesou, Anemone pseudoaltaica (Anemone pseudo-altaica H.Hara), Azumaichige (Anemone raddeana Regel), Yukiwariichige: Ruriichige (Anemone keiskeana T.Ito), Nirinsou: Gashousou (Anemone flaccida F.Schmidt), Sanrinsou (Anemone sto onifera Maxim), anemone narcissiflora (Anemone narcissiflora L.var nipponica Tamura), bifurcated Ichige:.. Oushikina (Anemone dichotoma L.), Anemone: safflower Okinagusa, Hanaichige (Anemone coronaria L.), Anemone Hupehensis: Kibunegiku (Anemone hupehensis Lemoine var. japonica (Thunb. ex Murray) Bowles et Stearn), anemone-Narukisshifurora-Narukisshifurora (Anemone narcissiflora var. narcissiflora), Ezonohakusan'ichige (Anemone narcissiflora var. sa halinensis), Shikokuichige (Anemone shikokiana), anemone-Demissa (Anemone demissa), anemone-Fupehenshisu (Anemone hupehensis var. hupehensis), button Ichige (Anemone coronaria), Hana anemone (Anemone blanda Schott et Kotschy), red Yae anemone (Anemone × fulgens Gay), such as Yabuichige (Anemone nemorosa L.) is known.

Plants as a raw material used in the present invention is not particularly limited as long as anemone plant, because such availability is relatively easy for and effectiveness, Ezoichige: broadleaf Himeichige (Anemone soyensis H.Boissieu), Himeichige : Himeichige Saw Nirinsou (Anemone debilis Fisch.): Gashousou it is preferable to use one or more selected from (Anemone flaccida F.Schmidt).

  In the present invention, the extract of the plant belonging to the genus Cypridina includes the original substance and the dried product of the plant belonging to the genus Genus, but it is preferable to use the extract extracted using various solvents. For extraction, any part of the leaves, flowers, seeds, roots, stems, buds, etc. may be used for the extraction. From the viewpoint of the effectiveness of the present invention, the whole plant including the season of flowers is used. Use it. In the extraction, the raw material may be used as it is, but considering the extraction effect, it is preferable to perform the extraction after performing processing such as shredding, drying, and pulverization. The extraction can be performed by immersing in an extraction solvent or by an extraction method using a supercritical fluid or a subcritical fluid. In order to increase the extraction effect, homogenization may be performed in stirring or an extraction solvent. The extraction temperature is suitably about 5 ° C. to the boiling point of the extraction solvent. The extraction time varies depending on the type of extraction solvent and the extraction temperature, but it is appropriate to set it to about 1 hour to 14 days.

  Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, and ethers such as ethyl ether and propyl ether. And solvents such as esters such as butyl acetate and ethyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these can be selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline, or the like may be used. Furthermore, you may use 1 type, or 2 or more types of supercritical fluids and subcritical fluids, such as water, a carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia. Among these extraction solvents, it is preferable to use one or two selected from water and ethanol from the viewpoint of the effect of the present invention.

  The above-mentioned extract of the plant belonging to the genus Cyprinus can be used as it is, but the concentrated and dried product can be used again by dissolving it in water or a polar solvent, and the physiological effects thereof are not impaired. It may be used after performing purification treatment such as decolorization, deodorization and desalting, and fractionation treatment by column chromatography. The above-mentioned extract of the plant belonging to the genus Cyprinus, the processed product thereof and the fractionated product thereof can be freeze-dried after each treatment and fractionation and dissolved and used at the time of use.

  Antioxidants containing the extract of the genus Cypridina as an active ingredient have excellent free radical scavenging effect and superoxide anion scavenging effect, prevent photo-aging of skin, etc., and have excellent antioxidant action Demonstrate.

  An anti-aging agent comprising an extract of the plant belonging to the genus Cyprinus as an active ingredient has excellent human dermal fibroblast activation action, human type I collagen production promotion action, and epidermal cell activation action, and is excellent in prevention and improvement of aging symptoms. Demonstrate the effect.

  An immunostimulant comprising an extract of a plant belonging to the genus Euthyrus as an active ingredient has an excellent human acute monocyte leukemia cell activation effect and exhibits an excellent immunostimulatory effect.

  The extract of the plant belonging to the genus Euglena has an excellent immunostimulatory effect, anti-aging effect, and antioxidant effect, and can be used as an external preparation for skin and an oral preparation.

  The compounding amount of the extract of the plant belonging to the genus Cyprinus genus can be adjusted depending on the type of skin external preparation or oral preparation, purpose of use, etc. , 0.0001 to 50.0 mass% is preferable with respect to the total amount, and more preferably 0.001 to 20.0 mass%.

  The dosage form of the external preparation for skin containing the extract of the plant belonging to the genus Cyprinus is arbitrary. For example, it can be provided as a solubilizing system such as lotion, an emulsifying system such as cream or emulsion, or a dispersing system such as calamine lotion. Further, it can be provided in various dosage forms such as aerosol, lipstick, and foundation filled with a propellant.

  In addition, the external preparation for skin blended with the extract is usually blended with pharmaceuticals, quasi-drugs, skin cosmetics, hair cosmetics and cleansing agents as needed, in addition to these extracts. Oily ingredients, moisturizers, powders, pigments, emulsifiers, solubilizers, detergents, UV absorbers, thickeners, drugs, fragrances, resins, antibacterial / antifungal agents, alcohols, etc. can be added as appropriate. .

  In addition, the dosage form of the oral preparation containing the extract of the plant belonging to the genus Cyprinus is arbitrary, but can also be provided in various dosage forms such as powders, granules, capsules, liquids, etc. Oily ingredients, moisturizers, powders, emulsifiers, solubilizers, thickeners, drugs, fragrances, antifungal agents, alcohols, sugar, condensed milk, Flour, salt, glucose, chicken egg, butter, margarine, starch syrup, calcium, iron, seasoning, spice, vitamin A and derivatives thereof, carotenoids, riboflavin and derivatives thereof, vitamin B and salts or derivatives thereof, ascorbic acid And derivatives thereof, cobalamins, vitamin E and derivatives thereof, vitamin K, adenosine and derivatives thereof, flavonoids and tannins can also be added.

  In the following, production examples of extracts of the plant belonging to the genus Eulysium, tests for evaluating each action, formulation examples as external preparations for skin and oral preparations will be explained in detail, but the technical scope of the present invention is not limited thereby. Is not to be done.

[Extract 1]
The whole plant including the season of Ezoichige flower was dried and pulverized, and 20 times the amount of the sample was added with a 50% by mass ethanol aqueous solution, followed by extraction with stirring at room temperature for 2 hours. The obtained extract was filtered to remove insolubles, concentrated under reduced pressure, and then freeze-dried to obtain extract 1.

[Extract 2]
The whole plant including the season of Ezoichige flower was dried and pulverized, purified water of 20 times the mass of the sample was added, and the mixture was extracted by heating to 120 ° C. for 20 minutes. From the obtained extract, insolubles were removed by suction filtration, and then lyophilized to obtain Extract 2.

[Extract 3]
The whole plant including the season of the flowers of Nirinsu was dried and pulverized, 20% by mass of the sample mass was added to a 50% by mass aqueous ethanol solution, and the mixture was extracted for 2 hours while stirring at room temperature. The obtained extract was filtered to remove insolubles, concentrated under reduced pressure, and then freeze-dried to obtain extract 3.

[Extract 4]
The whole plant including the season of Nirinsu flowers was dried and pulverized, purified water of 20 times the sample mass was added, and the mixture was extracted by heating to 120 ° C. for 20 minutes. From the obtained extract, insolubles were removed by suction filtration, and then freeze-dried to obtain extract 4.

<Evaluation of antioxidant effect by scavenging DPPH radical>
Using a 50% by mass aqueous ethanol solution, the solutions of Extract 2, Extract 3 and Extract 4 were adjusted to the sample concentrations shown in Table 1, and 100 μL each was added to a 96-well microplate. Thereto, 100 μL each of 0.2 mM 1,1-diphenyl-2-picrylhydrazyl (DPPH) ethanol solution was added, mixed well, and allowed to stand in the dark at room temperature for 24 hours. Finally, the absorbance at 516 nm derived from the DPPH radical was measured. When the absorbance when no extract was added was (A) and the absorbance when an extract was added was (B), the DPPH radical elimination rate was determined from the following equation.
Radical scavenging rate = {1- (B) / (A)} × 100
The evaluation results are shown in Table 1.

    As is apparent from Table 1, when the plant extract belonging to the genus Cyprinus was added, an excellent DPPH radical scavenging effect was observed.

<SOD-like activity evaluation (superoxide anion scavenging ability evaluation)>
A HANK'S (+) solution (75 μL) containing 0.25 mM tetrazolium salt (WST-1) and 1 mM hypoxanthine was prepared to the respective sample concentrations shown in Table 2 using the HANK'S (+) solution. 25 μL of solutions of Extract 2, Extract 3, and Extract 4 were added. Furthermore, xanthine oxidase (Xanthine Oxidase) 25 microliters (0.0075Units) was added, and after making it react at 37 degreeC for 15 minute (s), the light absorbency of 450 nm was measured. Superoxide anion elimination rate when (A) is the absorbance when only the HANK'S (+) solution is added instead of the extract solution, and (B) is the absorbance when the extract solution is added Was obtained from the following equation.
Erase rate (%) = {1- (B) / (A)} × 100
The obtained evaluation results are shown in Table 2.

  As can be seen from Table 2, when an extract of the plant belonging to the genus Cyprinus was added, an excellent superoxide anion scavenging effect was observed.

<Evaluation of human dermal fibroblast activation effect>
Normal human dermal fibroblasts were seeded in a 96-well microplate at 2.0 × 10 ⁴ cells per well. Dulbecco's modified Eagle medium (DMEM) supplemented with 1% by weight fetal bovine serum (FBS) was used as the seeding medium. After 24 hours, the sample culture solution was replaced with the extract 1, extract 2, extract 3, and extract 4 prepared at the respective sample concentrations shown in Table 3 in 1% mass FBS-added DMEM medium, and further 48 Incubate for hours. Next, the MTT reagent prepared in the medium to 400 μg / mL was added to the cells from which the supernatant was removed, and the cells were cultured for about 2 hours. Finally, formazan produced in 2-propanol was extracted and the absorbance at 550 nm was measured. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated using the difference between the two measured values. In the evaluation, in addition to the sample culture solution, 1% FBS-added DMEM medium was used as a negative control. The evaluation was performed by obtaining a relative value when the cell activation effect in the control was set to 100. The evaluation results are shown in Table 3. Note that the significance probability of less than 5% (P <0.05) is represented by * and the significance probability of less than 1% (P <0.01) is represented by ** with respect to the significance P value in the t-test.

  As is clear from Table 3, a significant dermal fibroblast activation effect was observed in the medium supplemented with the extract of the plant belonging to the genus Euglena.

[Dermal fibroblast type I collagen production promoting effect]
Normal human dermal fibroblasts were seeded in a 96-well microplate at 2.0 × 10 ⁴ cells per well. The seeding medium used was Dulbecco's modified Eagle (DMEM) medium supplemented with 5% by weight fetal bovine serum (FBS). After 24 hours, the medium was replaced with a sample culture solution containing the extract 3 adjusted to each concentration in a DMEM medium supplemented with 0.5 mass% FBS, and further cultured for 24 hours.
The amount of type 1 collagen secreted into the culture supernatant was determined by ELISA, and finally 2,2′-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) against labeled peroxidase. And after adding hydrogen peroxide and making it react, the light absorbency of 405 nm was measured with the microplate reader. In the evaluation, in addition to the sample culture solution, a DMEM medium supplemented with 0.5% FBS was used as a negative control.
The evaluation was performed by obtaining a relative value when the cell activation effect in the negative control was taken as 100. Specifically, the amount of protein was determined by measuring the amount of protein with BCA Protein Assay Kit manufactured by PIERCE, and the amount of collagen production per unit cell or unit protein was calculated. The value was determined.

  As shown in Table 4, the dermal fibroblast type I collagen production promoting action was observed in the medium supplemented with the extract of the genus Euthyrus.

[Epidermal cell activation]
Human epidermal non-keratinized cells (HaCaT cell) were seeded in a 96-well microplate so that there were 2.0 × 10 ⁴ cells per well. As the seeding medium, 5% by mass of fetal bovine serum (FBS) was added to Dulbecco's modified Eagle medium (DMEM). After 24 hours, the medium was replaced with the sample culture solution to which the extract 3 and the extract 4 were added so that the concentrations shown in Table 5 were obtained in a 5% by mass FBS-added DMEM medium, followed by further culturing for 24 hours.
Next, the MTT reagent was adjusted with the medium so as to be 400 μg / mL, exchanged, and cultured for about 2 hours. Finally, formazan produced in 2-propanol was extracted, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated using the difference between the two measured values. The evaluation was performed by obtaining a relative value when the cell activation effect in the control was set to 100. The results are shown in Table 5.

  As shown in Table 5, an epidermal cell activation effect was observed in the medium supplemented with the extract of the plant belonging to the genus Euthyrus.

<Immune activation effect (cell activation using human acute monocyte leukemia cell line)>
A human acute monocyte leukemia cell line (THP-1) was seeded on a 96-well microplate so that the number of human acute monocytic leukemia cell line (THP-1) was 5.0 × 10 ⁴ per well. As a seeding medium, Rpswell Park Memorial Institute medium (RPMI) supplemented with 1% by mass of FBS was used. After 24 hours, phorbol 12-myristate 13-acetate (PMA) was added to the cell culture to 20 ng / mL. Further, 24 hours later, the culture medium was added with the extract 3 and the extract 4 so as to have the concentrations shown in Table 6 in 1% by mass FBS-added RPMI medium and cultured for 48 hours. Next, RPMI medium supplemented with 1% by mass FBS to which 1/10 amount of living cell count reagent SF (Dojindo Laboratories) was added was added to the cells from which the supernatant had been removed, and cultured for 2 hours. After mixing, the absorbance at 450 nm was measured. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated using the difference between the two measured values. The evaluation results are shown in Table 6 as relative values when the cell activation effect in the control with no extract added is taken as 100.

  As shown in Table 6, a significant immunostimulatory effect was observed in the medium supplemented with the extract of the plant belonging to the genus Cyprinus.

  Then, the formulation example of a skin external preparation and a foodstuff is shown as a composition which mix | blended the extract of the genus Euglena according to the present invention.

[Formulation Example 1] Emulsion (1) Squalane 10.0 (mass%)
(2) Methylphenylpolysiloxane 4.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Polyoxyethylene monostearate
Sorbitan (20E.O.) 1.3
(6) Sorbitan monostearate 1.0
(7) Glycerin 4.0
(8) Methyl paraoxybenzoate 0.1
(9) Carboxyvinyl polymer 0.15
(10) Purified water 53.85
(11) Arginine (1% by weight aqueous solution) 20.0
(12) Extract 1 5.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification, cooling is started, and (11) and (12) are sequentially added and mixed uniformly.

[Prescription Example 2] Lotion (1) Ethanol 15.0 (mass%)
(2) Polyoxyethylene (40E.O.) hydrogenated castor oil 0.3
(3) Fragrance 0.1
(4) Purified water 78.38
(5) Citric acid 0.02
(6) Sodium citrate 0.1
(7) Glycerin 1.0
(8) Hydroxyethyl cellulose 0.1
(9) Extract 1 5.0
Production method: (2) and (3) are dissolved in (1). After dissolution, (4) to (8) are sequentially added, and then sufficiently stirred, (9) is added and mixed uniformly.

[Prescription Example 3] Cream (1) Squalane 10.0 (mass%)
(2) Stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Lipophilic glyceryl monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20 mass% aqueous solution) 15.0
(10) Purified water 36.7
(11) Carboxyvinyl polymer (1% by weight aqueous solution) 15.0
(12) Extract 2 5.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. (11) is added after completion | finish of emulsification, cooling is started, (12) is added at 40 degreeC, and it mixes uniformly.

[Formulation Example 4] Cosmetic liquid (1) Purified water 27.45 (mass%)
(2) Glycerin 10.0
(3) Sucrose fatty acid ester 1.3
(4) Carboxyvinyl polymer (1% by weight aqueous solution) 17.5
(5) Sodium alginate (1% by weight aqueous solution) 15.0
(6) Polyglyceryl monolaurate 1.0
(7) Macadamia nut oil fatty acid phytosteryl 3.0
(8) N-lauroyl-L-glutamic acid di (phytosteryl-2-octyldodecyl) 2.0
(9) Hardened palm oil 2.0
(10) Squalane (derived from olive) 1.0
(11) Behenyl alcohol 0.75
(12) Beeswax 1.0
(13) Jojoba oil 1.0
(14) 1,3-butylene glycol 10.0
(15) L-arginine (10% by mass aqueous solution) 2.0
(16) Extract 1 5.0
Production method: The aqueous phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. Cooling is started after completion of emulsification, and (15) is added at 50 ° C. Cool further to 40 ° C., add (16) and mix evenly.

[Formulation Example 5] Aqueous gel (1) Carboxyvinyl polymer 0.5 (mass%)
(2) Purified water 78.7
(3) Sodium hydroxide (10% by mass aqueous solution) 0.5
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Fragrance 0.1
(7) Extract 2 10.0
(8) Polyoxyethylene (60E.O.) hydrogenated castor oil 0.1
Manufacturing method: (1) is added to (2), and after stirring uniformly, (3) is added. After stirring uniformly, (5) previously dissolved in (4) is added. After stirring uniformly, the previously mixed (6) to (8) are added and stirred and mixed uniformly.

[Formulation Example 6] Cleansing Fee (1) Squalane 77.0 (mass%)
(2) Polyoxyethylene glyceryl isostearate 15.0
(3) Purified water 3.0
(4) Extract 1 5.0
Manufacturing method: (1) and (2) are uniformly dissolved. (3) and (4) are sequentially added to this and mixed uniformly.

[Formulation Example 7] Face-wash foam (1) Stearic acid 16.0 (mass%)
(2) Myristic acid 16.0
(3) Lipophilic glyceryl monostearate 2.0
(4) Glycerin 20.0
(5) Sodium hydroxide 7.5
(6) Palm oil fatty acid amidopropyl betaine 1.0
(7) Purified water 31.5
(8) Extract 2 6.0
Production method: The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the water phase components (5) to (7) are heated and dissolved at 80 ° C., and the oil phase components are uniformly mixed and stirred. Cooling is started, and (8) is added at 40 ° C. and mixed uniformly.

[Prescription Example 8] Make-up base cream (1) Squalane 10.2 (mass%)
(2) Cetanol 2.0
(3) Glycerin tri-2-ethylhexanoate 2.5
(4) Lipophilic glyceryl monostearate 1.0
(5) Propylene glycol 11.0
(6) Sucrose fatty acid ester 1.3
(7) Purified water 65.4
(8) Titanium oxide 1.0
(9) Bengala 0.1
(10) Yellow iron oxide 0.4
(11) Fragrance 0.1
(12) Extract 2 5.0
Production method: The oil phase components (1) to (4) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (5) to (7) are mixed and dissolved by heating at 75 ° C., and the pigments (8) to (10) are added thereto and uniformly dispersed with a homomixer. The oil phase component is added to the water phase component and emulsified with a homomixer. Cooling is started after the emulsification is completed, and the components (11) and (12) are added at 40 ° C. and mixed uniformly.

[Prescription Example 9] Emulsion foundation (1) Methylpolysiloxane 2.0 (mass%)
(2) Squalane 5.0
(3) Octyldodecyl myristate 5.0
(4) Cetanol 1.0
(5) Polyoxyethylene (20E.O.)
Sorbitan monostearate 1.3
(6) Sorbitan monostearate 0.7
(7) 1,3-butylene glycol 8.0
(8) Xanthan gum 0.1
(9) Methyl paraoxybenzoate 0.1
(10) Purified water 53.6
(11) Titanium oxide 9.0
(12) Talc 7.4
(13) Bengala 0.5
(14) Yellow iron oxide 1.1
(15) Black iron oxide 0.1
(16) Fragrance 0.1
(17) Extract 2 5.0
Production method: The oil phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are mixed and dissolved by heating at 75 ° C., and the pigments (11) to (15) are added thereto and uniformly dispersed with a homomixer. The oil phase component is added to the water phase component and emulsified with a homomixer. Cooling is started after the emulsification is completed, and components (16) and (17) are sequentially added at 40 ° C. and mixed uniformly.

[Prescription Example 10] Water-in-oil emollient cream (1) Liquid paraffin 30.0 (mass%)
(2) Microcrystalline wax 2.0
(3) Vaseline 5.0
(4) Diglycerin oleate 5.0
(5) Sodium chloride 1.3
(6) Potassium chloride 0.1
(7) Propylene glycol 3.0
(8) 1,3-butylene glycol 5.0
(9) Methyl paraoxybenzoate 0.1
(10) Extract 2 5.0
(11) Purified water 43.4
(12) Fragrance 0.1
Production method: Dissolve (5) and (6) in a part of (11) to 50 ° C, and gradually add to (4) heated to 50 ° C with stirring. After mixing this, it disperse | distributes uniformly to (1)-(3) heated and melt | dissolved at 70 degreeC. (7) to (10) are added to the remainder of (11) heated and dissolved at 70 ° C. with stirring, and emulsified with a homomixer. Cooling is started after completion of emulsification, and (12) is added at 40 ° C. and mixed uniformly.

[Prescription Example 11] Pack (1) Purified water 58.9 (mass%)
(2) Polyvinyl alcohol 12.0
(3) Ethanol 17.0
(4) Glycerin 5.0
(5) Polyethylene glycol (average molecular weight 1000) 2.0
(6) Extract 1 5.0
(7) Fragrance 0.1
Production method: (2) and (3) are mixed, heated to 80 ° C, and then dissolved in (1) heated to 80 ° C. After uniformly dissolving, add (4) and (5), and start cooling while stirring. Cool to 40 ° C, add (6) and (7) and mix uniformly.

[Prescription Example 12] Bath agent (1) Fragrance 0.3 (mass%)
(2) Extract 1 5.0
(3) Sodium bicarbonate 46.0
(4) Sodium sulfate 48.7
Production method: (1) to (4) are mixed uniformly.

[Prescription Example 13] Hair wax (1) Stearic acid 3.0 (mass%)
(2) Microcrystalline wax 2.0
(3) Cetyl alcohol 3.0
(4) Highly polymerized methylpolysiloxane 2.0
(5) Methylpolysiloxane 5.0
(6) Poly (oxyethylene / oxypropylene)
Methylpolysiloxane copolymer 1.0
(7) Methyl paraoxybenzoate 0.1
(8) 1,3-butylene glycol 7.5
(9) Arginine 0.7
(10) Purified water 70.6
(11) Extract 2 5.0
(12) Fragrance 0.1
Production method: The oil phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 75 ° C., the oil phase component is added, and the mixture is emulsified with a homomixer. Cooling is started after the emulsification is completed, and the components (11) and (12) are added at 40 ° C. and mixed uniformly.

[Prescription Example 14] Hairtonic (1) Ethanol 46.0 (mass%)
(2) Purified water 48.9
(3) Extract 1 5.0
(4) Fragrance 0.1
Production method: Components (1) to (4) are mixed and homogenized.

[Prescription Example 15] Beverage (1) Extract 2 8.0 (mass%)
(2) Erythritol 1.0
(3) Citric acid 0.1
(4) Stevia 0.01
(5) Purified water 90.89
Production method: (1) to (5) are mixed uniformly.

[Prescription Example 16] Tablet (1) Extract 1 0.30 (parts by mass)
(2) Reduced maltose starch syrup 0.53
(3) Corn starch 0.15
(4) Glycerin fatty acid ester 0.02
Production method: (1) to (3) were sieved and mixed, and (4) was further added and mixed. Tableting was performed with a tableting machine to obtain tablets with a total amount of 300 mg.

[Prescription Example 17] Emulsion (1) Squalane 10.0 (mass%)
(2) Methylphenylpolysiloxane 4.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Polyoxyethylene monostearate
Sorbitan (20E.O.) 1.3
(6) Sorbitan monostearate 1.0
(7) Glycerin 4.0
(8) Methyl paraoxybenzoate 0.1
(9) Carboxyvinyl polymer 0.15
(10) Purified water 53.85
(11) Arginine (1% by weight aqueous solution) 20.0
(12) Extract 3 5.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification, cooling is started, and (11) and (12) are sequentially added and mixed uniformly.

[Prescription Example 18] Lotion (1) Ethanol 15.0 (mass%)
(2) Polyoxyethylene (40E.O.) hydrogenated castor oil 0.3
(3) Fragrance 0.1
(4) Purified water 78.38
(5) Citric acid 0.02
(6) Sodium citrate 0.1
(7) Glycerin 1.0
(8) Hydroxyethyl cellulose 0.1
(9) Extract 3 5.0
Production method: (2) and (3) are dissolved in (1). After dissolution, (4) to (8) are sequentially added, and then sufficiently stirred, (9) is added and mixed uniformly.

[Prescription Example 19] Cream (1) Squalane 10.0 (mass%)
(2) Stearic acid 2.0
(3) Hydrogenated palm kernel oil 0.5
(4) Hydrogenated soybean phospholipid 0.1
(5) Cetanol 3.6
(6) Lipophilic glyceryl monostearate 2.0
(7) Glycerin 10.0
(8) Methyl paraoxybenzoate 0.1
(9) Arginine (20 mass% aqueous solution) 15.0
(10) Purified water 36.7
(11) Carboxyvinyl polymer (1% by weight aqueous solution) 15.0
(12) Extract 4 5.0
Production method: The oil phase components (1) to (6) are heated and dissolved at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. (11) is added after completion | finish of emulsification, cooling is started, (12) is added at 40 degreeC, and it mixes uniformly.

[Prescription Example 20] Cosmetic liquid (1) Purified water 27.45 (% by mass)
(2) Glycerin 10.0
(3) Sucrose fatty acid ester 1.3
(4) Carboxyvinyl polymer (1% by weight aqueous solution) 17.5
(5) Sodium alginate (1% by weight aqueous solution) 15.0
(6) Polyglyceryl monolaurate 1.0
(7) Macadamia nut oil fatty acid phytosteryl 3.0
(8) N-lauroyl-L-glutamic acid di (phytosteryl-2-octyldodecyl) 2.0
(9) Hardened palm oil 2.0
(10) Squalane (derived from olive) 1.0
(11) Behenyl alcohol 0.75
(12) Beeswax 1.0
(13) Jojoba oil 1.0
(14) 1,3-butylene glycol 10.0
(15) L-arginine (10% by mass aqueous solution) 2.0
(16) Extract 3 5.0
Production method: The aqueous phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. Cooling is started after completion of emulsification, and (15) is added at 50 ° C. Cool further to 40 ° C., add (16) and mix evenly.

[Prescription Example 21] Aqueous gel (1) Carboxyvinyl polymer 0.5 (mass%)
(2) Purified water 78.7
(3) Sodium hydroxide (10% by mass aqueous solution) 0.5
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Fragrance 0.1
(7) Extract 4 10.0
(8) Polyoxyethylene (60E.O.) hydrogenated castor oil 0.1
Manufacturing method: (1) is added to (2), and after stirring uniformly, (3) is added. After stirring uniformly, (5) previously dissolved in (4) is added. After stirring uniformly, the previously mixed (6) to (8) are added and stirred and mixed uniformly.

[Prescription Example 22] Cleansing Fee (1) Squalane 77.0 (mass%)
(2) Polyoxyethylene glyceryl isostearate 15.0
(3) Purified water 3.0
(4) Extract 3 5.0
Manufacturing method: (1) and (2) are uniformly dissolved. (3) and (4) are sequentially added to this and mixed uniformly.

[Prescription Example 23] Face-wash foam (1) Stearic acid 16.0 (mass%)
(2) Myristic acid 16.0
(3) Lipophilic glyceryl monostearate 2.0
(4) Glycerin 20.0
(5) Sodium hydroxide 7.5
(6) Palm oil fatty acid amidopropyl betaine 1.0
(7) Purified water 31.5
(8) Extract 4 6.0
Production method: The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the water phase components (5) to (7) are heated and dissolved at 80 ° C., and the oil phase components are uniformly mixed and stirred. Cooling is started, and (8) is added at 40 ° C. and mixed uniformly.

[Prescription Example 24] Make-up base cream (1) Squalane 10.2 (mass%)
(2) Cetanol 2.0
(3) Glycerin tri-2-ethylhexanoate 2.5
(4) Lipophilic glyceryl monostearate 1.0
(5) Propylene glycol 11.0
(6) Sucrose fatty acid ester 1.3
(7) Purified water 65.4
(8) Titanium oxide 1.0
(9) Bengala 0.1
(10) Yellow iron oxide 0.4
(11) Fragrance 0.1
(12) Extract 4 5.0
Production method: The oil phase components (1) to (4) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (5) to (7) are mixed and dissolved by heating at 75 ° C., and the pigments (8) to (10) are added thereto and uniformly dispersed with a homomixer. The oil phase component is added to the water phase component and emulsified with a homomixer. Cooling is started after the emulsification is completed, and the components (11) and (12) are added at 40 ° C. and mixed uniformly.

[Prescription Example 25] Emulsion foundation (1) Methylpolysiloxane 2.0 (mass%)
(2) Squalane 5.0
(3) Octyldodecyl myristate 5.0
(4) Cetanol 1.0
(5) Polyoxyethylene (20E.O.)
Sorbitan monostearate 1.3
(6) Sorbitan monostearate 0.7
(7) 1,3-butylene glycol 8.0
(8) Xanthan gum 0.1
(9) Methyl paraoxybenzoate 0.1
(10) Purified water 53.6
(11) Titanium oxide 9.0
(12) Talc 7.4
(13) Bengala 0.5
(14) Yellow iron oxide 1.1
(15) Black iron oxide 0.1
(16) Fragrance 0.1
(17) Extract 4 5.0
Production method: The oil phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are mixed and dissolved by heating at 75 ° C., and the pigments (11) to (15) are added thereto and uniformly dispersed with a homomixer. The oil phase component is added to the water phase component and emulsified with a homomixer. Cooling is started after the emulsification is completed, and components (16) and (17) are sequentially added at 40 ° C. and mixed uniformly.

[Formulation Example 26] Water-in-oil emollient cream (1) Liquid paraffin 30.0 (mass%)
(2) Microcrystalline wax 2.0
(3) Vaseline 5.0
(4) Diglycerin oleate 5.0
(5) Sodium chloride 1.3
(6) Potassium chloride 0.1
(7) Propylene glycol 3.0
(8) 1,3-butylene glycol 5.0
(9) Methyl paraoxybenzoate 0.1
(10) Extract 4 5.0
(11) Purified water 43.4
(12) Fragrance 0.1
Production method: Dissolve (5) and (6) in a part of (11) to 50 ° C, and gradually add to (4) heated to 50 ° C with stirring. After mixing this, it disperse | distributes uniformly to (1)-(3) heated and melt | dissolved at 70 degreeC. (7) to (10) are added to the remainder of (11) heated and dissolved at 70 ° C. with stirring, and emulsified with a homomixer. Cooling is started after completion of emulsification, and (12) is added at 40 ° C. and mixed uniformly.

[Prescription Example 27] Pack (1) Purified water 58.9 (mass%)
(2) Polyvinyl alcohol 12.0
(3) Ethanol 17.0
(4) Glycerin 5.0
(5) Polyethylene glycol (average molecular weight 1000) 2.0
(6) Extract 3 5.0
(7) Fragrance 0.1
Production method: (2) and (3) are mixed, heated to 80 ° C, and then dissolved in (1) heated to 80 ° C. After uniformly dissolving, add (4) and (5), and start cooling while stirring. Cool to 40 ° C, add (6) and (7) and mix uniformly.

[Prescription Example 28] Bath agent (1) Fragrance 0.3 (mass%)
(2) Extract 3 5.0
(3) Sodium bicarbonate 46.0
(4) Sodium sulfate 48.7
Production method: (1) to (4) are mixed uniformly.

[Prescription Example 29] Hair wax (1) Stearic acid 3.0 (mass%)
(2) Microcrystalline wax 2.0
(3) Cetyl alcohol 3.0
(4) Highly polymerized methylpolysiloxane 2.0
(5) Methylpolysiloxane 5.0
(6) Poly (oxyethylene / oxypropylene)
Methylpolysiloxane copolymer 1.0
(7) Methyl paraoxybenzoate 0.1
(8) 1,3-butylene glycol 7.5
(9) Arginine 0.7
(10) Purified water 70.6
(11) Extract 4 5.0
(12) Fragrance 0.1
Production method: The oil phase components (1) to (6) are mixed and dissolved by heating at 75 ° C. On the other hand, the aqueous phase components (7) to (10) are dissolved by heating at 75 ° C., the oil phase component is added, and the mixture is emulsified with a homomixer. Cooling is started after the emulsification is completed, and the components (11) and (12) are added at 40 ° C. and mixed uniformly.

[Prescription Example 30] Hairtonic (1) Ethanol 46.0 (mass%)
(2) Purified water 48.9
(3) Extract 3 5.0
(4) Fragrance 0.1
Production method: Components (1) to (4) are mixed and homogenized.

[Prescription Example 31] Beverage (1) Extract 4 8.0 (mass%)
(2) Erythritol 1.0
(3) Citric acid 0.1
(4) Stevia 0.01
(5) Purified water 90.89
Production method: (1) to (5) are mixed uniformly.

[Prescription Example 32] Tablet (1) Extract 3 0.30 (parts by mass)
(2) Reduced maltose starch syrup 0.53
(3) Corn starch 0.15
(4) Glycerin fatty acid ester 0.02
Production method: (1) to (3) were sieved and mixed, and (4) was further added and mixed. Tableting was performed with a tableting machine to obtain tablets with a total amount of 300 mg.

Claims (3)

An antioxidant comprising, as an active ingredient, an extract of one or two kinds of plants selected from Ezoichige and Nirinso . An anti-aging agent comprising, as an active ingredient, an extract of one or two kinds of plants selected from Ezoichige and Nirinso . An immunostimulant comprising, as an active ingredient, an extract of one or two kinds of plants selected from Ezoichige and Nirinso .